Central nervous system capillary haemangioblastoma: the pathologist's viewpoint
1Department of Pathology, Faculty of Medicine, Assuit University, Assuit University Hospitals, Assuit, Egypt. mrh17@swissinfo.org
International Journal of Experimental Pathology
|September 20, 2007
Summary
Haemangioblastomas, rare brain tumors, arise sporadically or with Von Hippel-Lindau disease (VHL). This review clarifies their diverse clinicopathology and histogenesis, aiding diagnosis.
Area of Science:
- Neuropathology
- Oncology
- Genetics
Background:
- Haemangioblastomas are rare intracranial neoplasms (1.5-2.5% of tumors), predominantly in the cerebellum, medulla, and spinal cord.
- While often sporadic, up to 25% are linked to Von Hippel-Lindau disease (VHL), an inherited genetic disorder.
- Existing literature lacks comprehensive analysis, hindering understanding of clinicopathologic diversity and histogenesis.
Purpose of the Study:
- To conduct a literature review on haemangioblastomas.
- To consolidate and analyze clinicopathologic features and histogenesis.
- To provide a clearer understanding of these rare tumors.
Main Methods:
- Literature review of Medline database.
- Inclusion of relevant monographs and clinicopathological case series.
- Analysis of reported haemangioblastoma cases.
Main Results:
- Haemangioblastomas occur sporadically (often with VHL gene somatic mutations) or as part of VHL disease (25-30%, inherited VHL gene mutation).
- Clinicopathologic presentations vary, with cerebellar lesions showing better prognosis than brainstem tumors.
- Immunostaining aids differentiation; neoplastic 'stromal' cells overexpress vascular endothelial growth factors, driving vascularity and extramedullary hematopoiesis.
Conclusions:
- Haemangioblastomas exhibit diverse presentations and origins, linked to VHL gene mutations.
- Prognosis differs based on tumor location.
- Understanding neoplastic stromal cell function is key to histogenesis and potential therapeutic targets.
